Navigation Links
Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals
Date:6/19/2013

NEW YORK, June 19, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals
http://www.reportlinker.com/p0925641/Partnerships-Licensing-Investments-and-MA-Deals-and-Trends-for-May-2013-in-Pharmaceuticals.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Investment_Banking

Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals

Summary

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in May 2013. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the last six months.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Pharmaceuticals & Healthcare, Global, Deal Summary, 7
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, May 2013 7
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, May 2013 9
2.2.1 Valeant Pharma to Acquire Bausch & Lomb for US$8.7 Billion 9
2.2.2 Actavis to Acquire Warner Chilcott for US$8.5 Billion 10
2.2.3 Royalty Pharma Increases Its Offer Price to Acquire Elan 10
2.2.4 Merck Completes Public Offering of Notes for $6.5 Billion 11
2.2.5 Pfizer Completes Public Offering of Notes for US$4 Billion 11
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, May 2013 12
2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, May 2013 13
3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 14
3.1 Pharmaceuticals & Healthcare, Global, M&A, May 2013 14
3.1.1 Top M&A Deals in May 2013 15
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, December 2012–May 2013 16
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, May 2013 17
3.2.1 Top Equity Offering Deals in May 2013 18
3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, December 2012–May 2013 19
3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, May 2013 20
3.3.1 Top PE/VC Deals in May 2013 21
3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, May 2013 22
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, May 2013 23
3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, December 2012–May 2013 25
3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, December 2012–May 2013 26
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, May 2013 27
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, May 2013 27
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, December 2012–May 2013 28
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), May 2013 29
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, May 2013 30
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), December 2012–May 2013 31
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, December 2012–May 2013 32
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), December 2012–May 2013 33
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), December 2012–May 2013 34
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, May 2013 35
5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, May 2013 35
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 36
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, May 2013 37
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, May 2013 37
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, May 2013 38
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), December 2012–May 2013 39
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), December 2012–May 2013 40
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), December 2012–May 2013 41
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), December 2012–May 2013 43
6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 44
6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, May 2013 44
6.1.1 Oncology – Deals of the Month 45
6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, May 2013 46
6.2.1 Central Nervous System – Deals of the Month 47
6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, May 2013 48
6.3.1 Infectious Diseases – Deals of the Month 49
6.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, May 2013 50
6.4.1 Cardiovascular – Deal of the Month 51
6.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorder Deals, May 2013 52
6.5.1 Metabolic Disorders – Deal of the Month 53
6.6 Pharmaceuticals & Healthcare, Global, Immunology Deals, May 2013 54
6.6.1 Immunology – Deal of the Month 55
6.7 Pharmaceuticals & Healthcare, Global, Respiratory, Deals, May 2013 56
6.7.1 Respiratory – Deal of the Month 57
7 Deal Summary by Geography 58
7.1 Pharmaceuticals & Healthcare, North America Deals, May 2013 58
7.1.1 North America – Deals of the Month 59
7.2 Pharmaceuticals & Healthcare, Europe, Deals, May 2013 60
7.2.1 Europe – Deals of the Month 61
7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, May 2013 62
7.3.1 Asia-Pacific – Deals of the Month 63
7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, May 2013 64
7.4.1 Rest of the World – Deals of the Month 65
8 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 66
8.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, December 2012–May 2013 66
8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, December 2012–May 2013 67
9 Further Information 68
9.1 Methodology 68
9.2 About GlobalData 69
9.3 Contact Us 69
9.4 Disclosure information 69
9.5 Disclaimer 69

List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), December 2012–May 2013 8
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, May 2013 9
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), May 2013 13
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), December 2012–May 2013 14
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, May 2013 15
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, December 2012– May 2013 16
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), December 2012–May 2013 17
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, May 2013 18
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), December 2012–May 2013 19
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), December 2012–May 2013 20
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, May 2013 21
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, December 2012–May 2013 22
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), May 2013 24
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), December 2012– May 2013 25
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, December 2012–May 2013 26
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), December 2012– May 2013 27
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), December 2012–May 2013 28
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), December 2012–May 2013 29
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 30
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), December 2012–May 2013 31
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, December 2012–May 2013 33
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), December 2012–May 2013 34
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), December 2012–May 2013 35
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), December 2012–May 2013 36
Table 25: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, May 2013 37
Table 26: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, May 2013 37
Table 27: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, May 2013 38
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), December 2012–May 2013 39
Table 29: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), May 2013 40
Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, December 2012–May 2013 42
Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), May 2013 43
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), December 2012– May 2013 45
Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), December 2012–May 2013 47
Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), December 2012–May 2013 48
Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), December 2012–May 2013 50
Table 36: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), December 2012–May 2013 52
Table 37: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), December 2012– May 2013 54
Table 38: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), December 2012–May 2013 56
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), December 2012–May 2013 59
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), December 2012–May 2013 60
Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), December 2012–May 2013 62
Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), December 2012–May 2013 64
Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), December 2012–May 2013 66
Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), December 2012–May 2013 67

List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), December 2012–May 2013 7
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), May 2013 12
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), May 2013 13
Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$ m), December 2012–May 2013 14
Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, December 2012–May 2013 16
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), December 2012–May 2013 17
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), December 2012–May 2013 19
Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), December 2012–May 2013 20
Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, December 2012–May 2013 22
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), May 2013 23
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), May 2013 24
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), December 2012–May 2013 25
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), December 2012–May 2013 27
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), December 2012–May 2013 28
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), December 2012–May 2013 29
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), December 2012–May 2013 31
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, December 2012–May 2013 32
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, December 2012–May 2013 33
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), December 2012–May 2013 34
Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), December 2012–May 2013 35
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), December 2012–May 2013 36
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), December 2012–May 2013 39
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), December 2012–May 2013 40
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, December 2012–May 2013 41
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), December 2012–May 2013 42
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), May 2013 43
Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), December 2012–May 2013 44
Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), December 2012–May 2013 46
Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), December 2012–May 2013 48
Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), December 2012–May 2013 50
Figure 31: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), December 2012–May 2013 52
Figure 32: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), December 2012–May 2013 54
Figure 33: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), December 2012–May 2013 56
Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), December 2012–May 2013 58
Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), December 2012–May 2013 60
Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), December 2012–May 2013 62
Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), December 2012–May 2013 64
Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), December 2012–May 2013 66
Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), December 2012–May 2013 67

To order this report:
Investment_Banking Industry: Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals


Contact Clare: clare@reportlinker.com  
US:(339) 368 6001
Intl:+1 339 368 6001


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved


Related medicine technology :

1. Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2012
2. Biotech Strategy 2012 - Licensing, Collaboration, and M&A Trends
3. MGT Capital Investments, Inc. Announces Sale of Medicsight Patents
4. MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference
5. Medical Equipment Annual Deals Analysis: M&A and Investments Trends - 2012
6. Frost & Sullivan: Government Support Vital to Encourage Venture Capital Investments in the North American Healthcare Industry
7. Physicians Capital Investments Receives "Outstanding Development Award" for Sandy, Oregon Project
8. Proposed Regulatory Uniformity to Boost Venture Capital Investments in Healthcare Arena, Says Frost & Sullivan
9. Kerry R. Hicks Joins Physicians Capital Investments as Vice-Chairman of Board
10. Frost & Sullivan: Investments in Healthcare Improvements to Bolster the Integration of Picture Archiving and Communications Systems in Latin America
11. Government Investments in Upgrades Sustain Laboratory Analytical Instrumentation Market in China, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Ambulances announces its first delivery in the state of ... Emergency Medical Services (EMS) consisting of four vehicles: three ... Emergency Vehicles in Lecanto, FL , USA, ... the latest in Demers, ongoing expansion of sales.  ... --> Benoit LaFortune , Executive Vice President at Demers. ...
(Date:2/12/2016)... Mass. , Feb. 12, 2016   HeartWare ... a conference call and webcast to discuss its financial ... 31, 2015, on Thursday, February 25, 2016 at 8:00 ... results prior to the conference call and webcast.  On ... company,s financial results, highlights from the fourth quarter and ...
(Date:2/12/2016)... VIEJO , Kalifornien, 12. Februar 2016 /PRNewswire/ ... mit der Aufnahme von Patienten für eine Studie ... von Aneurysmen („WEB") speziell für die Behandlung von ... Spelle , MD, Leiter der Neuroradiologie an der ... Frankreich, und Hauptprüfarzt der CLARYS-Studie hat den ersten ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... , ... According to an article published February 4th on mySA, ... of hernia repairs throughout the United States. Commenting on this article, Beverly Hills hernia ... trend has not only been expected, but it seems to be a natural result ...
(Date:2/12/2016)... ... ... The law firm of Morrow, Morrow, Ryan & Bassett is offering scholarships ... is to encourage applicants to pursue a degree in their field of study and ... , “We have available jobs in St. Landry and Evangeline Parishes that can be ...
(Date:2/12/2016)... Raton, FL (PRWEB) , ... February 12, 2016 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – hosted over 250 members of South Florida’s philanthropic community at its ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fixed ... p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination , Fixed ... pharmaceutical products, garnering increased attention from all stakeholders in the development of new ...
(Date:2/12/2016)... Angeles, CA (PRWEB) , ... February 12, 2016 , ... ... With a hectic schedule, a demanding job, and no time to decompress, Rabinowitz found ... she dedicated herself to meditation for its impact on her life, implementing a 20-minute-per-day ...
Breaking Medicine News(10 mins):